methyl 2-(4-isopropylphenyl)acetate | 16216-94-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: methyl 2-(4-isopropylphenyl)acetate
• 英文别名: Methyl-4-isopropylphenylacetat；(4-isopropyl-phenyl)-acetic acid methyl ester；(4-Isopropyl-phenyl)-essigsaeure-methylester；p-isopropylphenylacetic acid methyl ester；Methyl α,α-dimethyl-p-tolylacetate；methyl 4-isopropylphenylacetate；methyl 2-(4-propan-2-ylphenyl)acetate
• CAS: 16216-94-7
• 化学式: C₁₂H₁₆O₂
• 分子量: 192.258
• InChiKey: YPVRHVMAGVVRCI-UHFFFAOYSA-N

物化性质

• 沸点：
  256.5±9.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-isopropylphenyl)acetate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 4-异丙基苯乙酸
  参考文献：
  名称：

  闭环烯烃-烯烃交叉偶联反应合成大内酰胺

  摘要：

  本文报道的是一种通过Rh（III）催化的闭环烯烃-烯烃交叉偶联反应合成大内酰胺的实用方法。反应是通过Rh催化的烯基sp 2 C–H活化过程进行的，该过程允许接触不同环大小的大环分子。含有共轭二烯骨架的大内酰胺可以很容易地以高化学选择性和Z，E立体选择性制备。

  DOI：

  10.1021/acs.orglett.0c03801
• 作为产物：
  描述：

  4'-异丙基苯乙酮 在 硫酸 作用下， 生成 methyl 2-(4-isopropylphenyl)acetate
  参考文献：
  名称：

  宝石-二氟和单氟烯烃的脱氟反应。用于生成醛、羧酸和酯的羰基化合物的单碳同系化的新方法

  摘要：

  通过羰基化合物的简便二氟亚甲基化可轻松制备偕二氟烯烃 (1) 的脱氟水解（或醇解），得到羧酸（或酯）。将同源性方法应用于抗炎布洛芬的合成。此外，通过还原 1 获得的单氟烯烃的脱氟水解得到醛。

  DOI：

  10.1246/cl.1980.651

文献信息

• .beta.-thiopropionyl-aminoacid derivatives and their use as
  申请人：SmithKline Beecham p.l.c.

  公开号：US06048852A1

  公开（公告）日：2000-04-11

  A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, heterocyclyl or heterocyclyl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, where m is 0 to 3, n is 1 to 3, each R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-4)alkyl and X is O, S(O).sub.x where x is 0-2, or a bond; R.sub.4 is hydrogen, or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.p where p is 2 to 5. Some compounds are claimed per se.

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。
• The Discovery of <i>N</i>-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-<i>N</i>′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist
  作者：Martin H. Bolli、Christoph Boss、Christoph Binkert、Stephan Buchmann、Daniel Bur、Patrick Hess、Marc Iglarz、Solange Meyer、Josiane Rein、Markus Rey、Alexander Treiber、Martine Clozel、Walter Fischli、Thomas Weller

  DOI：10.1021/jm3009103

  日期：2012.9.13

  medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ETB receptor and shows excellent

  从波生坦（1）的结构开始，我们着手于一项药物化学程序，旨在鉴定具有高口服功效的新型有效的双重内皮素受体拮抗剂。这导致发现了一系列新的烷基磺酰胺取代的嘧啶。其中，化合物17（macitentan，ACT-064992）引起了人们的特别关注，因为它是对ET B受体具有显着亲和力的ET A的有效抑制剂，并且在高血压Dahl盐敏感性大鼠中显示出优异的药代动力学特性和高体内功效。化合物17成功完成了一项肺动脉高压的长期III期临床试验。
• A Convenient and General Synthesis of 2-Aryl- and 2-Pyridyl-3-oxo-3,4-dihydro-2<i>H</i>-1,4-benzothiazines
  作者：Niels Jacobsen、Hans Kolind-Andersen

  DOI：10.1055/s-1990-27051

  日期：——

  The reaction of bis(2-aminophenyl) disulphide 1 with methyl or ethyl aryl- or pyridylacetates and sodium hydride gives the title compounds in good yield and high purity. The reaction is general, the starting materials easily available and the workup is simple and rapid

  双（2-氨基苯基）二硫化物1与甲基或乙基芳基或吡啶乙酸盐及氢化钠的反应在良好的产率和高纯度下生成该标题化合物。该反应具有通用性，起始材料易于获得，后处理简单快速。
• Novel adenine compound and use thereof
  申请人：Isobe Yoshiaki

  公开号：US20060052403A1

  公开（公告）日：2006-03-09

  A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X 1 represents oxygen, sulfur, NR 1 (R 1 represents hydrogen or alkyl), or a single bond; Y 1 represents a single bond, alkylene, etc.; Y 2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q 1 and Q 2 represents —COOR 10 (wherein R 10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

  一种适用于局部给药的药物，作为抗过敏剂有效。该药物含有一种腺嘌呤化合物作为活性成分，该化合物由通式（1）表示：[其中环A表示6-10个成员、单环或双环、芳香烃或含有1-3个杂原子（选自0-2个氮原子、0或1个氧原子和0或1个硫原子）的5-10个成员、单环或双环、芳香杂环；n为0-2的整数；m为0-2的整数；R表示卤素、（未）取代的烷基等；X1表示氧、硫、NR1（R1表示氢或烷基）或单键；Y1表示单键、亚烷基等；Y2表示单键、亚烷基等；Z表示亚烷基；Q1和Q2中至少一个表示—COOR10（其中R10表示（未）取代的烷基等），等等]或该化合物的药学上可接受的盐。
• Compounds and Methods For Treatment of Thrombosis
  申请人：Deng Hongfeng

  公开号：US20080146811A1

  公开（公告）日：2008-06-19

  The invention provides compounds, pharmaceutical compositions, and methods for the treatment of thromboembolic disorders, such as, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the chambers of the heart.

  本发明提供了用于治疗血栓栓塞性疾病的化合物、制药组合物和方法，例如，动脉心血管血栓栓塞性疾病、静脉心血管血栓栓塞性疾病或心脏房室的血栓栓塞性疾病。